Literature DB >> 15206731

T cell apoptosis by kynurenines.

Francesca Fallarino1, Ursula Grohmann, Carmine Vacca, Ciriana Orabona, Antonio Spreca, Maria C Fioretti, Paolo Puccetti.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme that, expressed by different cell types, has regulatory effects on T cells resulting from tryptophan depletion in specific local tissue microenvironments. The discovery that inhibition of IDO activity reduces the survival of MHC-mismatched fetuses in mice and that the risk of fetal allograft rejection correlates with the degree of parental tissue incompatibility has led to the hypothesis that IDO activity protects fetal allografts from maternal T cell-mediated immunity. Different mechanisms, however, might contribute to IDO-dependent immune regulation. We have found that tryptophan metabolites in the kynurenine pathway, such as 3-hydroxyanthranilic and quinolinic acids, will induce the selective apoptosis in vitro of murine thymocytes and Th1 but not Th2 cells. T cell apoptosis was observed at relatively low concentrations of kynurenines, did not require Fas/Fas ligand interactions and was associated with the activation of casapase-8 and the release of cytochrome c from mitochondria. In vivo, the two kynurenines caused depletion of specific thymocyte subsets in a fashion qualitatively similar to dexamethasone. These data may represent the first experimental evidence for the involvement of tryptophan catabolism in the regulation of T cell apoptosis and maintenance of peripheral T cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15206731     DOI: 10.1007/978-1-4615-0135-0_21

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  82 in total

1.  Kynurenine pathway metabolites: relevant to vitamin B-6 deficiency and beyond.

Authors:  Matthew A Ciorba
Journal:  Am J Clin Nutr       Date:  2013-08-28       Impact factor: 7.045

Review 2.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Authors:  Diwakar Davar; Nathan Bahary
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

4.  Infectious tolerance via the consumption of essential amino acids and mTOR signaling.

Authors:  Stephen P Cobbold; Elizabeth Adams; Claire A Farquhar; Kathleen F Nolan; Duncan Howie; Kathy O Lui; Paul J Fairchild; Andrew L Mellor; David Ron; Herman Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

Review 5.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 6.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 7.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

8.  Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis.

Authors:  Kashif Asghar; John Brain; Jeremy M Palmer; Stephen Douglass; Fatmah M A Naemi; Graeme O'Boyle; John Kirby; Simi Ali
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

9.  DC expressing transgene Foxp3 are regulatory APC.

Authors:  Michael W Lipscomb; Jennifer L Taylor; Cristina J Goldbach; Simon C Watkins; Amy K Wesa; Walter J Storkus
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

10.  Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens.

Authors:  Maneesh Mailankot; Magdalena M Staniszewska; Heather Butler; Moonkyung H Caprara; Scott Howell; Benlian Wang; Catherine Doller; Lixing W Reneker; Ram H Nagaraj
Journal:  Lab Invest       Date:  2009-03-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.